Chronic Kidney Disease, Experimental Models, Biomarkers, Precision Medicine 3

15 Apr 2024 5:45 p.m. 6:45 p.m.
MON-073 to MON-088
Time Session
5:45 p.m.
6:45 p.m.
KIDNEY ELASTOMETRY AND X-FLOW ALGORITHMS: NEW METHODS TO INTERROGATE THE PROTEINURIA AND EFFECTS OF EMPAGLIFLOZIN
WCN24-AB-1365, Poster Board= MON-073
MON-073
Poster PresenterPietro Iulianiello
A PROSPECTIVE STUDY TO ANALYSE THE ACCURACY OF ESTIMATED GFR EQUATIONS AS COMPARED TO MEASURED GFR BY IOHEXOL CLEARANCE IN PATIENTS WITH LIVER CIRRHOSIS.
WCN24-AB-1597, Poster Board= MON-074
MON-074
Poster PresenterMadhuri Kashyap
TO DETERMINE THE EFFICACY OF LACTOFERRIN IN IMPROVING HEMOGLOBIN LEVELS IN CHRONIC KIDNEY DISEASE PATIENTS WITH IRON DEFICIENCY ANEMIA
WCN24-AB-1323, Poster Board= MON-075
MON-075
Poster PresenterMadhuri Kashyap
THE EFFECT OF LACTOFERRIN ON HEMOGLOBIN, ERYTHROFERRONE AND HEPCIDIN LEVELS IN CHRONIC KIDNEY DISEASE
WCN24-AB-1274, Poster Board= MON-076
MON-076
Poster PresenterMadhuri Kashyap
INHIBITION OF ANGIOPOIETIN-2 COMBINED WITH A HIGH LEVEL OF ANGIOTENSIN-II EXACERBATES RENAL FIBROSIS
WCN24-AB-782, Poster Board= MON-077
MON-077
Poster PresenterAn Jie Luo
NOVEL BIOMARKERS AND PREDICTION OF KIDNEY DISEASE PROGRESSION IN AUSTRALIAN FIRST NATION PEOPLE WITH AND WITHOUT DIABETES: THE eGFR STUDY
WCN24-AB-1077, Poster Board= MON-078
MON-078
Poster PresenterRichard Macisaac
THE ROLE OF OXYSTEROL-BINDING PROTEIN LIKE 7 IN PODOCYTE HEALTH: IMPLICATIONS IN CHRONIC KIDNEY DISEASE PATHOPHYSIOLOGY
WCN24-AB-1213, Poster Board= MON-079
MON-079
Poster PresenterJeffrey Pressly
PIRFENIDONE DOWNREGULATES RENAL FIBROGENESIS AND INFLAMMATION SLOWING CKD PROGRESSION IN AN EXPERIMENTAL MODEL OF HYPERTENSIVE NEPHROSCLEROSIS
WCN24-AB-1335, Poster Board= MON-080
MON-080
Poster PresenterAna Laura Rubio Francini
EARLY PREDICTION OF FRAILTY, FUNCTIONAL IMPAIRMENT, AND MORTALITY WITH NON-INVASIVE BIOELECTRICAL IMPEDANCE ANALYSIS IN ECUADORIAN HEMODIALYSIS PATIENTS
WCN24-AB-1818, Poster Board= MON-081
MON-081
Poster PresenterJuan Cristóbal Santacruz Mancheno
ASSESSMENT OF THE EFFECT OF HEPATIC IMPAIRMENT ON IPTACOPAN PHARMACOKINETICS
WCN24-AB-748, Poster Board= MON-082
MON-082
Poster PresenterRobert Schmouder
PHARMACOKINETICS OF SINGLE DOSES OF IPTACOPAN
WCN24-AB-555, Poster Board= MON-083
MON-083
Poster PresenterRobert Schmouder
SINGLE DOSE OF IPTACOPAN TREATMENT RAPIDLY DESCREASES PLASMA COMPLEMENT Bb LEVELS
WCN24-AB-550, Poster Board= MON-084
MON-084
Poster PresenterRobert Schmouder
ASSESSMENT OF CORRELATION BETWEEN 24-HOUR URINARY SODIUM EXCRETION AND 24-HOUR AMBULATORY BLOOD PRESSURE IN HEALTHY SUBJECTS AND CHRONIC KIDNEY DISEASE PATIENTS
WCN24-AB-231, Poster Board= MON-085
MON-085
Poster PresenterJohn Abraham Tharayil
THE EFFECTS OF HYPOXIA-INDUCIBLE FACTOR-2 INACTIVATION IN MURINE KIDNEY DISEASE MODELS
WCN24-AB-796, Poster Board= MON-086
MON-086
Poster PresenterPei-Zhen Tsai
SAFETY AND EFFICACY OF IPTACOPAN IN ADOLESCENT PATIENTS WITH IDIOPATHIC (PRIMARY) IMMUNE-COMPLEX-MEDIATED MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)
WCN24-AB-1146, Poster Board= MON-087
MON-087
Poster PresenterNicholas Webb
THE RISK FACTORS OF COVID-19 ADVERSE OUTCOME AND FOLLOW-UP TWO-YEAR SURVIVAL RATE IN PATIENTS ON MAINTENANCE HEMODIALYSIS
WCN24-AB-837, Poster Board= MON-088
MON-088
Poster PresenterEugene Zeltyn-Abramov